acute promyelocytic leukaemia
Haematology · 2009–2015
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| arsenic trioxide First-line treatment of acute promyelocytic leukaemia (APL) in combination with ATRA±chemotherapy, in addition to relapsed APL. | Nov 2015 | Recommended with restriction | none received |
| arsenic trioxide Induction and consolidation treatment of relapsed acute promyelocytic leukaemia (characterised by the presence of the t(15:17) translocation or PML/RAR-α… | Mar 2009 | Recommended with restriction | no section in document |
| arsenic trioxide Induction and consolidation treatment of relapsed acute promyelocytic leukaemia (APL) characterised by the presence of the t(15:17) translocation or PML/RAR-α… | Mar 2009 | Recommended with restriction | no section in document |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| arsenic trioxideArsenic trioxide for treating acute promyelocytic leukaemia | TA526 | recommended | 2018-06 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.